Core Insights - Palisade Bio, Inc. is developing PALI-2108, the first and only PDE4 inhibitor designed for targeted delivery to the terminal ileum and colon, addressing unmet needs in ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD) [1][7] - The Crohn's & Colitis Foundation has approved a strategic equity investment of up to $500,000 in Palisade to support the clinical development of PALI-2108 [1][2] Company Overview - Palisade Bio is a clinical-stage biopharmaceutical company focused on next-generation, once-daily oral PDE4 inhibitor prodrugs aimed at improving pharmacology, tolerability, and convenience for patients with inflammatory and fibrotic diseases [5][6] - The company is advancing PALI-2108 for moderate-to-severe UC and FSCD, with a recent Phase 1b trial showing a 100% clinical response in the UC cohort and no serious adverse events [7][8] Product Development - PALI-2108 is designed for local delivery of PDE4 inhibition, becoming active only in the lower intestine, which minimizes systemic exposure and enhances therapeutic effects [3][7] - The company has completed several Phase 1 studies and is preparing for Phase 2 Investigational New Drug (IND) submissions to the FDA in 2026 [2][8]

Market Performance - U.S. stocks experienced gains, with the Dow Jones index increasing by 1.66% to 49,183.51, the NASDAQ rising by 0.80% to 23,420.85, and the S&P 500 up by 0.81% to 6,913.76 [1] - European shares also saw positive movement, with the eurozone's STOXX 600 gaining 0.94%, Spain's IBEX 35 Index rising by 0.70%, London's FTSE 100 up by 0.54%, Germany's DAX increasing by 1.34%, and France's CAC 40 climbing by 0.20% [5] - Asian markets closed mostly higher, highlighted by Japan's Nikkei 225 gaining 2.97% and China's Shanghai Composite surging 1.38%, while India's BSE Sensex fell by 0.38% [6] Commodity Prices - In commodity trading, oil prices increased by 1.7% to $58.30, gold rose by 2.9% to $4,454.40, silver surged by 7.3% to $76.230, and copper climbed by 5.1% to $5.9815 [4] Company Developments - Momentus Inc (NASDAQ:MNTS) shares surged by 57% to $8.98 following the announcement of an additive-manufactured fuel tank for flight testing [8] - GH Research PLC (NASDAQ:GHRS) shares increased by 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application for GH001 [8] - VerifyMe Inc (NASDAQ:VRME) shares rose by 66% to $1.12 due to a strategic merger letter of intent with Open World [8] - Zenas Biopharma Inc (NASDAQ:ZBIO) shares dropped by 57% to $14.94 after announcing results from the Phase 3 INDIGO trial [8] - Palisade Bio Inc (NASDAQ:PALI) shares fell by 16% to $2.10, and Palvella Therapeutics Inc (NASDAQ:PVLA) decreased by 14% to $86.16 [8] Economic Indicators - The ISM manufacturing PMI declined for the third consecutive month to 47.9 in December, marking the lowest reading since October 2024, down from 48.2 in November and below market estimates of 48.3 [2][7]

U.S. Stock Market Performance - U.S. stocks traded higher, with the Dow Jones index gaining more than 250 points, closing up 1.66% at 49,183.51 [1] - The NASDAQ increased by 0.80% to 23,420.85, and the S&P 500 rose by 0.81% to 6,913.76 [1] Sector Performance - Energy shares experienced a gain of 2.9% on Monday [1] - Utilities stocks saw a decline of 2.2% [1] Commodity Market - Oil prices rose by 1.7% to $58.30 [4] - Gold increased by 2.9% to $4,454.40 [4] - Silver surged by 7.3% to $76.230, while copper rose by 5.1% to $5.9815 [4] European Market Performance - European shares were higher, with the eurozone's STOXX 600 gaining 0.94% [5] - Spain's IBEX 35 Index rose by 0.70%, London's FTSE 100 increased by 0.54%, Germany's DAX gained 1.34%, and France's CAC 40 climbed 0.20% [5] Asian Market Performance - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 2.97% [6] - Hong Kong's Hang Seng Index increased by 0.03%, China's Shanghai Composite surged by 1.38%, while India's BSE Sensex fell by 0.38% [6] Company-Specific Developments - Momentus Inc (NASDAQ:MNTS) shares surged 57% to $8.98 following the announcement of an additive-manufactured fuel tank for flight testing [8] - GH Research PLC (NASDAQ:GHRS) shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application [8] - VerifyMe Inc (NASDAQ:VRME) shares increased by 66% to $1.12 due to a strategic merger letter of intent with Open World [8] - Zenas Biopharma Inc (NASDAQ:ZBIO) shares dropped 57% to $14.94 after announcing Phase 3 INDIGO trial results [8] - Palisade Bio Inc (NASDAQ:PALI) shares fell 16% to $2.10, and Palvella Therapeutics Inc (NASDAQ:PVLA) decreased by 14% to $86.16 [8]

Company Performance - Ultragenyx Pharmaceutical Inc. shares fell 42% to $19.84 following the announcement of Phase 3 study results for setrusumab (UX143) in Osteogenesis Imperfecta (OI) [1] - Mereo BioPharma Group plc shares dropped 90% to $0.23 after its Phase 3 studies for setrusumab did not achieve statistical significance against primary endpoints [5] Market Movements - Republic Power Group Ltd surged 163% to $0.69 [5] - Brand Engagement Network Inc jumped 84.3% to $2.21 after entering a Vendor Services Project Agreement [5] - DigitalBridge Group Inc rose 9.9% to $15.30 following the announcement of its acquisition by SoftBank Group for approximately $4.0 billion [5] Precious Metals Sector - Hycroft Mining Holding Corporation was down 14% to $21.61 as precious metal stocks traded lower due to a retreat in commodity prices [6] - Silver prices pulled back after reaching an all-time high, impacting related stocks [6]

Group 1 - U.S. stocks experienced a decline, with the Nasdaq Composite dropping over 100 points on Monday [1] - DigitalBridge Group Inc announced its acquisition by SoftBank Group for an enterprise value of approximately $4.0 billion, resulting in a 9.9% increase in its shares to $15.30 [1] Group 2 - Eightco Holdings Inc shares surged 29.1% to $2.15 following the announcement of a share buyback program for up to $125 million [2] - Palisade Bio Inc saw an 18.6% increase to $2.55 after Piper Sandler initiated coverage with an Overweight rating and a price target of $25 [2] - Regencell Bioscience Holdings Ltd gained 16.3% to $24.60 [2] - Praxis Precision Medicines Inc surged 13% to $304.00 after receiving Breakthrough Therapy Designation from the FDA for ulixacaltamide [2] - Zura Bio Ltd increased by 13% to $5.26 [2] - Precigen Inc rose 8.6% to $4.52 [2] - Autolus Therapeutics PLC jumped 7.8% to $1.80, with Needham analyst raising the price target from $10 to $11 [2] - LightPath Technologies Inc gained 6.6% to $9.62 [2] - NGL Energy Partners LP surged 6.3% to $9.98 [2] - Six Flags Entertainment Corp increased by 5% to $15.64 [2]

Core Insights - Palisade Bio Inc. (NASDAQ:PALI) has shown strong performance, with a 5.26% increase in stock price to $2.20, marking a four-day winning streak as investors anticipate clinical trial results for its treatment of fibrostenotic Crohn's disease (FSCD) [1][4] - The company plans to present topline results from its Phase 1b study of PALI-2108 in Q1 2026, with an Investigational New Drug submission expected in the first half of the following year [2] - The stock rally is partly attributed to window-dressing activities by institutional investors, who adjust their portfolios before reporting periods [3] Company Performance - Year-to-date, Palisade Bio Inc.'s shares have increased by 33.33% [4] - The company is focused on developing a next-generation oral PDE4 inhibitor prodrug aimed at treating inflammatory and fibrotic diseases [4]

Core Insights - Palisade Bio (PALI) is a clinical-stage biopharmaceutical company focused on developing PALI-2108, a prodrug candidate aimed at treating ulcerative colitis (UC) and fibrostenotic Crohn's disease (FSCD), both of which have significant unmet medical needs [1] Company Overview - PALI-2108 is being studied for two indications related to inflammatory bowel disease (IBD), specifically targeting ulcerative colitis and fibrostenotic Crohn's disease [1] Market Opportunity - The conditions targeted by PALI-2108 represent significant unmet medical needs, indicating a potential market opportunity for the company [1]

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - A SPAC III Acquisition Corp. (ASPC) has increased by 227% to $34.30 [3] - Enveric Biosciences, Inc. (ENVB) has risen by 113% to $12.65 [3] - ESH Acquisition Corp. (ESHA) is up 32% at $15.57 [3] - SU Group Holdings Limited (SUGP) has also increased by 32% to $8.20 [3] - Horizon Space Acquisition I Corp. (HSPO) is up 31% at $23.03 [3] - Mawson Infrastructure Group Inc. (MIGI) has risen by 18% to $5.45 [3] - Velo3D, Inc. (VELO) is up 17% at $7.72 [3] - Braze, Inc. (BRZE) has increased by 16% to $35.73 [3] - Cadrenal Therapeutics, Inc. (CVKD) is up 10% at $11.00 [3] - Palisade Bio, Inc. (PALI) has risen by 10% to $2.10 [3] Group 2: Premarket Losers - Aimei Health Technology Co., Ltd (AFJK) has decreased by 46% to $47.00 [4] - JX Luxventure Group Inc. (JXG) is down 33% at $5.73 [4] - Oriental Culture Holding LTD (OCG) has fallen by 29% to $7.21 [4] - Lakeland Industries, Inc. (LAKE) is down 26% at $11.06 [4] - WORK Medical Technology Group LTD (WOK) has decreased by 19% to $4.50 [4] - ReTo Eco-Solutions, Inc. (RETO) is down 16% at $2.73 [4] - Exicure, Inc. (XCUR) has fallen by 11% to $6.43 [4] - Denali Therapeutics Inc. (DNLI) is down 7% at $18.21 [4] - SMJ International Holdings Inc. (SMJF) has decreased by 7% to $4.50 [4] - Cracker Barrel Old Country Store, Inc. (CBRL) is down 6% at $25.30 [4]

Group 1 - U.S. stock futures are higher, with Dow futures gaining around 50 points [1] - Tilray Brands Inc announced a one-for-10 reverse stock split, effective December 1 [1] - Tilray shares fell sharply by 15% to $0.88 in pre-market trading [2] Group 2 - Inventiva ADR fell 7.4% to $4.26 in pre-market trading after a previous gain [4] - Anglogold Ashanti PLC dipped 5.5% to $83.97 in pre-market trading after a gain of over 5% [4] - Lexicon Pharmaceuticals Inc fell 5% to $1.36 in pre-market trading [4] - SuperX AI Technology Ltd fell 3.9% to $26.00 in pre-market trading after a significant previous jump of 23% [4] - Palisade Bio Inc declined 3.6% to $2.15 in pre-market trading [4] - Gold Fields Ltd fell 3.4% to $41.76 in pre-market trading after a gain of 6% [4] - Abacus Global Management Inc fell 3.2% to $6.33 in pre-market trading after reporting better-than-expected third-quarter results and announcing a $10 million buyback [4]

Group 1 - U.S. stock futures are higher, with Dow futures gaining approximately 50 points [1] - Tilray Brands Inc shares fell sharply by 15% to $0.88 in pre-market trading after announcing a one-for-10 reverse stock split [2][1] - The reverse stock split for Tilray was approved in June and will take effect on December 1 [1] Group 2 - Inventiva ADR shares decreased by 7.4% to $4.26 in pre-market trading after a previous gain of 4% [4] - Anglogold Ashanti PLC shares dipped by 5.5% to $83.97 after gaining over 5% on Wednesday [4] - Lexicon Pharmaceuticals Inc shares fell by 5% to $1.36 in pre-market trading [4] - SuperX AI Technology Ltd shares declined by 3.9% to $26.00 after a significant increase of 23% on Wednesday due to a $20 million share repurchase program announcement [4] - Palisade Bio Inc shares decreased by 3.6% to $2.15 in pre-market trading [4] - Gold Fields Ltd shares fell by 3.4% to $41.76 after a 6% gain on Wednesday [4] - Abacus Global Management Inc shares declined by 3.2% to $6.33 after reporting better-than-expected third-quarter results and announcing a $10 million buyback [4]